Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummet ~90%. See why I changed my rating ...

Cassava Sciences announced that the phase 3 trial of its Alzheimer's drug, simufilam, did not meet its primary endpoints.

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

This week, Cassava Sciences reported the failure of its latest Phase III trial of its experimental drug, simufilam—a drug ...

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

The company's future now appears to be in flux, as simufilam was its only drug in clinical trials, The New York Times reported. Also: a Roche lung cancer drug has failed to improve survival; pharma ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Opinion writers tackle these public health issues.

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) from Buy to Neutral. Analyst Price Forecast Suggests 2,654.83% Upside As of ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...